XenoFinder is a specialty CRO providing drug biotransformation services to pharma, biotech, and research institutions worldwide. We operate in Suzhou, China, and North Wales, PA, USA. Our leadership team includes seasoned biotransformation scientists with deep expertise in metabolite profiling and structural elucidation. With 150+ peer-reviewed publications and broad experience across pharma and CRO sectors, we bring a strong scientific foundation and proven project success.

Equipped with state-of-the-art LC-MS and radiodetection systems, XenoFinder specializes in metabolite identification and radiolabeled ADME studies. We support both small molecules and emerging modalities—including ADCs, peptides, oligonucleotides, PROTACs, and covalent drugs—across all stages of drug discovery, development, and regulatory submission.

Our study designs are tailored to meet the unique needs of each client’s program, and our project execution is driven by the perspective of drug development and regulatory submission.